Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Most Read

  1. UCLH initiates new trial for Alzheimer’s treatment in UK
  2. The highs and lows of hormone replacement therapy
  3. From Parkinson’s to asthma: opportunities for microbiome-based therapeutics
  4. Pharma Technology Focus – Special Issue
  5. Pharma Technology Focus – Issue 75

Latest Content

Flexible Drug Containers for Parenteral Drugs

Self-medication is becoming more popular, driven by cost considerations. Valuable time of healthcare personnel and the high cost of hospital stays are outweighing the costs of treatment drastically.

Europe’s updated guidelines on atopic dermatitis

The latest update to the consensus-based European guidelines for the treatment of atopic dermatitis in adults and children was published in May this year, replacing the previous set of European guidelines published in July 2012.

Trial design should give Dermira’s AD drug a better shot at Phase IIb success

Dermira’s lebrikizumab Phase IIb trial for atopic dermatitis (AD) has a better shot at statistical and clinical significance with the exclusion of corticosteroid, a class of steroid hormone, use. The outcome should be able to beat efficacy results of Roche’s previous proof-of-concept (POC) trial that tested lebrikizumab with corticosteroids and only achieved a 20% difference versus placebo, the inactive drug or treatment used in a clinical trial.

Roche makes a cautious investment in Ionis’ dAMD drug

Following up on Roche’s first partnership with Ionis Pharmaceuticals for an early-stage pipeline asset for Huntington’s disease, the two companies have signed a second deal, this time focusing on IONIS-FB-LRx, an antisense pipeline drug using Ionis’ advanced Ligand Conjugated Antisense (LICA) technology, which reduces the production of Factor B, a key protein in the complement innate immune system in a broad range of diseases.

ESMO 2018: previewing high-impact, late-breaking abstracts

The 2018 European Society for Medical Oncology (ESMO) Annual Congress will begin in Munich on October 19, where combination therapies and immuno-oncology strategies feature heavily in the highest impact clinical research abstracts. The best studies at the congress, those considered cutting-edge or practice-changing, will be presented during the three plenary sessions, called Presidential Symposia at ESMO.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top